Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
116K
-
Shares change
-
-17.2K
-
Total reported value, excl. options
-
$234K
-
Value change
-
-$204K
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$2.00
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q4 2022
15 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2022.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 116K shares
of 805K outstanding shares and own 14.4% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (97.2K shares), Virtu Financial LLC (17.7K shares), UBS Group AG (831 shares), BlackRock Inc. (50 shares), AllSquare Wealth Management LLC (21 shares), Federation des caisses Desjardins du Quebec (19 shares), NATIONAL BANK OF CANADA /FI/ (7 shares), Advisory Services Network, LLC (6 shares), TCI Wealth Advisors, Inc. (5 shares), and GABLES CAPITAL MANAGEMENT INC. (1 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.